Materials and methods for identifying spinal muscular atrophy carriers

Patent metadata

Field	Value
Publication number	US-11279977-B2
Application number	US-201815984659-A
Country	US
Kind code	B2
Filing date	May 21, 2018
Priority date	Jun 7, 2011
Publication date	Mar 22, 2022
Grant date	Mar 22, 2022

Abstract

Materials and methods for identifying carriers of genetic determinants of spinal muscular atrophy are disclosed. In particular, polymorphisms in linkage disequilibrium are associated as markers of spinal muscular atrophy alleles detectable by various techniques, including multiplex ligation-dependent probe analysis, sequence analysis, and RFLP detection. The materials and methods of the disclosure are particularly useful in identifying silent (2+0) carriers of spinal muscular atrophy in which two copies of the SMN1 gene are located on a single human chromosome 5 and no copies of the gene are located on the chromosome 5 homolog.

First claim

What is claimed is:

1. A method of determining if a human subject is highly likely to be a carrier of an SMN1 gene duplication, the method comprising:
(a) obtaining a nucleic acid sample from the subject;
(b) screening the nucleic acid sample using restriction fragment length polymorphism (RFLP) analysis after prior PCR amplification of the nucleic acid using primers SMN1-E7F (SEQ ID NO: 20) and SMN1-17R1 (SEQ ID NO: 24) to identify the nucleotide present at position 27134 of SEQ ID NO:1 in the nucleic acid sample from the subject; and
(c) determining that the subject is highly likely to be a carrier of an SMN1 duplication if the nucleotide present at position 27134 of SEQ ID NO:1 is a G.

2. A method of determining if a human subject is highly likely to be a Spinal Muscular Atrophy (SMA) silent (2+0) carrier, the method comprising:
(a) screening a nucleic acid from a human subject using restriction fragment length polymorphism (RFLP) analysis after prior PCR amplification of the nucleic acid using primers SMN1-E7F (SEQ ID NO: 20) and SMN1-17R1 (SEQ ID NO: 24) to determine if the nucleotide present at position 27134 of SEQ ID NO:1 is a G; and
(b) determining that the subject is highly likely to be a SMA silent (2+0) carrier if the nucleotide present at position 27134 of SEQ ID NO:1 is a G.

3. The method according to claim 2 further comprising obtaining a sample of nucleic acid from the human subject.

4. The method according to claim 2 further comprising providing genetic counseling to the human subject based on the results of the method of identifying a human Spinal Muscular Atrophy (SMA) silent (2+0) carrier.

5. The method according to claim 2 , further comprising determining the identity of the nucleotide present at position 11678 of SEQ ID NO:1; and determining if there is a nucleotide inserted between the nucleotides present at positions 11678 and 11679 of SEQ ID NO:1; and determining that the subject is highly likely to be a SMA silent (2+0) carrier if the nucleotide present at position 11678 of SEQ ID NO:1 is not a G or there is a nucleotide inserted between the nucleotides present at positions 11678 and 11679 of SEQ ID NO:1.

6. The method according to claim 2 , further comprising determining the identity of the nucleotide present at position 15774 of SEQ ID NO:1; and determining if there is a nucleotide inserted between the nucleotides present at positions 15774 and 15775 of SEQ ID NO:1; and determining that the subject is highly likely to be a SMA silent (2+0) carrier if the nucleotide present at position 15774 of SEQ ID NO:1 is not a G or there is a nucleotide inserted between the nucleotides present at positions 15774 and 15775 of SEQ ID NO:1.

7. The method according to claim 2 , further comprising determining the identity of the nucleotide present at position 22804 of SEQ ID NO:1; and determining if there is a nucleotide inserted between the nucleotides present at positions 22804 and 22805 of SEQ ID NO:1; and determining that the subject is highly likely to be a SMA silent (2+0) carrier if the nucleotide present at position 22804 of SEQ ID NO:1 is not a G or there is a nucleotide inserted between the nucleotides present at positions 22804 and 22805 of SEQ ID NO:1.

8. The method according to claim 2 , further comprising determining the identity of the nucleotide present at position 26190 of SEQ ID NO:1; and determining if there is a nucleotide inserted between the nucleotides present at positions 26190 and 26191 of SEQ ID NO:1; and determining that the subject is highly likely to be a SMA silent (2+0) carrier if the nucleotide present at position 26190 of SEQ ID NO:1 is not an A or there is a nucleotide inserted between the nucleotides present at positions 26190 and 26191 of SEQ ID NO:1.

9. The method according to claim 2 , further comprising determining whether the A-T dinucleotide present at positions 27706-27707 of SEQ ID NO:1 is present; and determining that the human subject is highly likely to be a SMA silent (2+0) carrier if the A-T dinucleotide present at positions 27706-27707 of SEQ ID NO:1 is not present.

10. A method of determining if a human subject is highly likely to be a Spinal Muscular Atrophy (SMA) silent (2+0) carrier, the method comprising:
(a) screening a nucleic acid from a human subject using restriction fragment length polymorphism (RFLP) analysis after prior PCR amplification of the nucleic acid using primers SMN1-E7F (SEQ ID NO: 20) and SMN7-17R1 (SEQ ID NO: 24) to identify the nucleotide present at position 27134 of SEQ ID NO:1 in the nucleic acid;
(b) determining if the A-T dinucleotide corresponding to positions 27706-27707 of SEQ ID NO:1 is present; and
(c) determining that the subject is highly likely to be a SMA silent (2+0) carrier if the nucleotide present at position 27134 of SEQ ID NO:1 is a G and the A-T dinucleotide normally present at positions 27706-27707 of SEQ ID NO:1 is not present.

11. The method according to claim 10 further comprising obtaining a sample of nucleic acid from the human subject.

12. The method according to claim 10 further comprising providing genetic counseling to the human subject based on the results of the method of identifying a human Spinal Muscular Atrophy (SMA) silent (2+0) carrier.

13. The method according to claim 10 wherein a G is identified at the position corresponding to position 27134 of SEQ ID NO:1 by restriction fragment length polymorphism using restriction endonuclease HpyCH4III.

Assignees

• Icahn School Med Mount Sinai

Inventors

• Edelmann Lisa
• Desnick Robert J

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6827

  for detection of mutation or polymorphism · CPC title

• C12Q2600/172

  Haplotypes · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title